Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control.

MLA

Lepore, Giuseppe, et al. “Switching to the Minimed™ 780G System Achieves Clinical Targets for CGM in Adults with Type 1 Diabetes Regardless of Previous Insulin Strategy and Baseline Glucose Control.” Acta Diabetologica, vol. 59, no. 10, Oct. 2022, pp. 1309–15. EBSCOhost, https://doi.org/10.1007/s00592-022-01937-5.

APA

Lepore, G., Rossini, A., Bellante, R., Corsi, A., Scaranna, C., Dodesini, A. R., & Trevisan, R. (2022). Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control. Acta Diabetologica, 59(10), 1309–1315. https://doi.org/10.1007/s00592-022-01937-5

Chicago

Lepore, Giuseppe, Alessandro Rossini, Rosalia Bellante, Anna Corsi, Cristiana Scaranna, Alessandro Roberto Dodesini, and Roberto Trevisan. 2022. “Switching to the Minimed™ 780G System Achieves Clinical Targets for CGM in Adults with Type 1 Diabetes Regardless of Previous Insulin Strategy and Baseline Glucose Control.” Acta Diabetologica 59 (10): 1309–15. doi:10.1007/s00592-022-01937-5.